Related Experiment Video
Updated: Aug 1, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
Xanthohumol exerts protective function on adriamycin-induced podocyte injury
Huihui Chen1,2, Hongzhou Lin1,2, Rengcheng Qian1,2
1Department of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xanthohumol (XN) protects against nephrotic syndrome by reducing podocyte injury. This natural compound may offer a new therapeutic option for kidney disease patients.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Nephrotic syndrome (NS) is a leading cause of end-stage renal disease (ESRD).
- Podocyte injury is a key factor in NS progression and proteinuria.
- Identifying novel therapeutic agents for podocyte protection is crucial.
Purpose of the Study:
- To investigate the protective effects of xanthohumol (XN) against podocyte injury.
- To evaluate XN's potential in mitigating adriamycin-induced nephropathy (AN).
Main Methods:
- Established in vivo and in vitro models of adriamycin (ADR)-induced podocyte injury.
- Utilized biochemical assays, PAS staining, immunohistochemistry, immunofluorescence, western blot, and RT-qPCR to assess XN's effects.
- Analyzed the impact of XN on podocyte-specific markers and injury indicators.
Main Results:
- XN upregulated key podocyte markers: Wilms' tumor protein 1 (Wt1), Nephrin, Synaptopodin, Zonula occludens 1 (ZO-1), and Crumbs2 (Crb2).
- XN downregulated the podocyte injury marker Desmin.
- XN treatment mitigated podocyte actin cytoskeleton disruption in ADR-treated models.
Conclusions:
- Xanthohumol (XN) significantly attenuated adriamycin-induced podocyte injury.
- XN demonstrates potential as a therapeutic strategy for nephrotic syndrome (NS).
- Further research into XN for NS treatment is warranted.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
DNA Damage Can Stall the Cell Cycle
Muscle Recovery and Fatigue
Oxygen Requirements and Growth Patterns
Cellular Injury I: Introduction
